Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial
Name:
Body composition changes....pdf
Size:
929.5Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Pegington, MaryZhen Tam, H.
Brentnall, A.
Sestak, I.
Adams, J.
Blake, G. M.
Gareth, Evans D
Howell, Anthony
Cuzick, J.
Harvie, Michelle
Affiliation
Division of Cancer Sciences, School of Medical Sciences, Medicine and Health, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK. Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, 555 Wilmslow Road, Manchester, UK. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
BACKGROUND: Uptake to anastrozole for breast cancer prevention is low, partly due to women's concerns about side effects including gains in weight and specifically gains in body fat. Previous evidence does not link anastrozole with gains in weight, but there is a lack of data on any effects on body composition i.e. changes in fat and fat free mass. Here we assess association of anastrozole with body composition changes in a prospective sub-study from the second international breast intervention trial (IBIS-II). METHODS: Participants had DXA scans at baseline and for five years of anastrozole/placebo and beyond (between March 2004 and September 2017. Primary outcomes were changes in body weight, body fat and fat free mass at 9-18 months. A linear model was used to estimate the size of a differential effect in these outcomes by randomised treatment allocation adjusted for baseline value and time since last scan, age, 10-year breast cancer risk, smoking and HRT status. RESULTS: 203 postmenopausal women were recruited (n = 95 anastrozole, n = 108 placebo), mean age 58 years (SD = 5.4), BMI 28.0 kg/m(2) (SD = 5.5). There was no evidence of a strong association between anastrozole or placebo and endpoints at 9-18 months; effect size (95 %CI) for anastrozole minus placebo for body weight (per/kg) -0.11 (-1.29-1.08); body fat 0.11 (-0.75-0.96) and fat free mass -0.30 (-0.79-0.19). CONCLUSIONS: There is unlikely to be a clinically significant change to body composition with anastrozole for breast cancer prevention.Citation
Pegington M, Zhen Tam H, Brentnall A, Sestak I, Adams J, Blake GM, et al. Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial. Preventive medicine reports. 2024 Feb;38:102620. PubMed PMID: 38375161. Pubmed Central PMCID: PMC10874867 personal relationships that could have appeared to influence the work reported in this paper. Epub 2024/02/20. eng.Journal
Preventive Medicine ReportsDOI
10.1016/j.pmedr.2024.102620PubMed ID
38375161Additional Links
https://dx.doi.org/10.1016/j.pmedr.2024.102620Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.pmedr.2024.102620